Cochlear, Demant contest UK regulator's Oticon deal concerns

Cochlear

20/03/2023 10:53

March 20 (Reuters) - The UK's anti-trust regulator said
on Monday that hearing device maker Cochlear  COH.AX  and
Copenhagen-based Demant  DEMANT.CO  had denied that the
Australian firm's purchase of Demant's hearing implants business
would lead to any competition concerns.
    The Competition and Markets Authority (CMA) said in a
statement that both Demant and Cochlear contested the
regulator's Phase 1 findings that other hearing solutions are
not good alternatives for bone conduction implants.
    The CMA has set a June 5 deadline for its in-depth phase 2
probe into Cochlear's purchase of Demant's Oticon Medical
business.

 (Reporting by Aby Jose Koilparambil in Bengaluru; Editing by
Maju Samuel)
 ((abyjose.koilparambil@thomsonreuters.com; +919986528692;))